- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01777867
Cough Reflex Sensitivity and Bronchial Hyper-responsiveness
16 février 2017 mis à jour par: Kenneth R. DeVault, M.D., Mayo Clinic
Pilot Studies Evaluating Cough Reflex Sensitivity and Bronchial Hyper-responsiveness: The Road to Cough and Wheeze in Patients With Gastroesophageal Reflux.
The aim of this study is to provide pilot data on the possible gastrointestinal predictors of respiratory hyper-responsiveness and how these relate to the clinical sub-types of gastroesophageal reflux disease (GERD) and visceral acid hypersensitivity.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Description détaillée
This study recruited participants into three groups: reflux patients with non-erosive disease (NERD) with abnormal levels of acid reflux, NERD patients with normal levels of reflux and healthy volunteers.
Participants were assessed for cough reflex sensitivity (CRS) to citric acid and bronchial-hyperresponsiveness (BHR) to methacholine challenge, both before (baseline) and after esophageal acid infusion (HCl, 0.15M) or normal saline control (8ml/min).
The order of CRS and BHR was randomized, as was the order of the acid/saline infusions.
Type d'étude
Observationnel
Inscription (Réel)
24
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Florida
-
Jacksonville, Florida, États-Unis, 32224
- Mayo Clinic Florida
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans à 60 ans (Adulte)
Accepte les volontaires sains
Oui
Sexes éligibles pour l'étude
Tout
Méthode d'échantillonnage
Échantillon de probabilité
Population étudiée
This study will recruit participants into three groups ages 18-60 years: 12 reflux patients with non-erosive disease (NERD) with abnormal levels of acid reflux, 12 NERD patients with normal levels of reflux and 12 healthy volunteers.
La description
Inclusion Criteria:
- symptomatic reflux (i.e., one symptom at least one day a week, with at least 'moderate' severity)
- no evidence of esophagitis
- non-smokers
Exclusion Criteria:
- previous gastrointestinal surgery (excluding minor surgeries, such as cholecystectomy, appendectomy
- active peptic ulcer disease
- Zollinger Ellison Syndrome
- Barrett's esophagus
- eosinophilic esophagitis
- cardiac disease
- diabetes or neurological deficit
- use of tricyclics
- selective serotonin reuptake inhibitors
- narcotics or benzodiazepines
- current use of medications that may affect symptoms of perception,lower esophageal sphincter basal pressure, acid clearance time or acid suppression
- antibiotics within 60 days
- Nursing mothers will be excluded
- allergies to citrus
- asthma
- chronic lung disease
- heart attack or stroke within the last three months
- hypersensitivity to methacholine products
- know aortic aneurysm
- uncontrolled hypertension (defined as systolic pressure greater than 200 or diastolic greater than 100)
- reduced pulmonary function test (forced expiratory volume in one second (FEV1) or the FEV1 to forced vital capacity (FVC) ratio (FEV1/FVC) of less that 70% of predicted value)
- None of the controls will have any GERD symptoms or ever used antireflux treatment.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Healthy Volunteers
Subjects in this arm were healthy volunteers.
Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
|
Subjects inhaled increasing concentrations of citric acid, which induces coughing in a dose-dependent, reproducible matter.
Following each inhalation, the number of coughs in the subsequent 15 seconds was counted and recorded.
The challenge was terminated once the citric acid induced 5 or more coughs and the logarithmic (base 10) concentration provoking 5 coughs was recorded.
A baseline spirometry was used to assess how well the participant's lungs work by measuring how much air was inhale, how much was exhale and how quickly the participant exhaled.
If this was normal, the subject inhaled slowly and deeply the methacholine test solution from a nebulizer and was told to hold their breath for 5 seconds.
This was repeated until 5 inhalations were performed in no more than two minutes.
|
|
Non-erosive reflux disease with reflux
Subjects enrolled in this arm had non-erosive reflux disease with reflux (heartburn) for at least 6 of the preceding 12 months.
Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
|
Subjects inhaled increasing concentrations of citric acid, which induces coughing in a dose-dependent, reproducible matter.
Following each inhalation, the number of coughs in the subsequent 15 seconds was counted and recorded.
The challenge was terminated once the citric acid induced 5 or more coughs and the logarithmic (base 10) concentration provoking 5 coughs was recorded.
A baseline spirometry was used to assess how well the participant's lungs work by measuring how much air was inhale, how much was exhale and how quickly the participant exhaled.
If this was normal, the subject inhaled slowly and deeply the methacholine test solution from a nebulizer and was told to hold their breath for 5 seconds.
This was repeated until 5 inhalations were performed in no more than two minutes.
|
|
Non-erosive reflux disease without reflux
Subjects enrolled in this arm had non-erosive reflux disease with normal levels of reflux (heartburn).
Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
|
Subjects inhaled increasing concentrations of citric acid, which induces coughing in a dose-dependent, reproducible matter.
Following each inhalation, the number of coughs in the subsequent 15 seconds was counted and recorded.
The challenge was terminated once the citric acid induced 5 or more coughs and the logarithmic (base 10) concentration provoking 5 coughs was recorded.
A baseline spirometry was used to assess how well the participant's lungs work by measuring how much air was inhale, how much was exhale and how quickly the participant exhaled.
If this was normal, the subject inhaled slowly and deeply the methacholine test solution from a nebulizer and was told to hold their breath for 5 seconds.
This was repeated until 5 inhalations were performed in no more than two minutes.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Change in cough reflex sensitivity (CRS)
Délai: baseline, approximately 4 weeks
|
baseline, approximately 4 weeks
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Kenneth R. DeVault, MD, Mayo Clinic
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
1 décembre 2012
Achèvement primaire (Réel)
1 février 2016
Achèvement de l'étude (Réel)
1 février 2016
Dates d'inscription aux études
Première soumission
24 janvier 2013
Première soumission répondant aux critères de contrôle qualité
24 janvier 2013
Première publication (Estimation)
29 janvier 2013
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
17 février 2017
Dernière mise à jour soumise répondant aux critères de contrôle qualité
16 février 2017
Dernière vérification
1 février 2017
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système digestif
- Maladies des voies respiratoires
- Troubles respiratoires
- Maladies gastro-intestinales
- Maladies bronchiques
- Signes et symptômes respiratoires
- Troubles de la motricité oesophagienne
- Troubles de la déglutition
- Maladies de l'oesophage
- Reflux gastro-oesophagien
- Toux
- Hyperréactivité bronchique
- Effets physiologiques des médicaments
- Agents neurotransmetteurs
- Mécanismes moléculaires de l'action pharmacologique
- Agents autonomes
- Agents du système nerveux périphérique
- Agents cholinergiques
- Agonistes cholinergiques
- Agents du système respiratoire
- Miotiques
- Parasympathomimétiques
- Agents bronchoconstricteurs
- Agonistes muscariniques
- Chlorure de méthacholine
Autres numéros d'identification d'étude
- 11-006873
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .